



CODIGO : 172151
NOMBRE PACIENTE : IAN MATEO HUERTAS ALVARADO **SEXO :** MASCULINO
FECHA DE NACIMIENTO : 01/12/2025 **REGISTRO CIVIL :** 1,077,342,840
NOMBRE RESPONSABLE : KELLY JOHANA ALVARADO CASTRO
DOC.IDENTIDAD DE LA MADRE : 1,003,474,897
FECHA TOMA DE MUESTRA : 31/01/2026 **TIPO DE MUESTRA :** TALÓN
FECHA DE IMPRESIÓN : 18/02/2026 **PESO :** 3720

TAMIZAJE NEONATAL

ANÁLISIS MUESTRA DE SANGRE

| | RESULTADO | VALORES DE REFERENCIA | INTERPRETACIÓN |
|---|-----------|---|--|
| T.S.H Neonatal | 1.69 | >= 6 µl/mL talón en prematuros >= 10 µl/mL talón >= 15 µl/mL cordón | Normal |
| Deficiencia de G6PDH | 5.70 | > 2.6 U/gHb | Normal |
| <i>TÉCNICA: Fluoroimmunoensayo (Delfia).</i> | | | <i>Procesado en Colombia por PREGEN.</i> |
| Hemoglobinopatías | FA | Ausencia de hemoglobinas anormales | Normal |
| <i>TÉCNICA: Cromatografía Líquida de Alto Rendimiento (HPLC).</i> | | | <i>Procesado en Colombia por PREGEN.</i> |

TAMIZAJE AMPLIADO

ESPECTROMETRIA DE MASAS EN TANDEM

Procesado en Archimedlife international medical laboratory. 1110 Vienna.

DESORDENES DE AMINOÁCIDOS

Citrulina, Metionina, Leucina, Isoleucina, Valina, Fenilalanina, Tirosina.

Ausencia de metabolitos anormales Normal

PERFIL DE ACILCARNITINAS

C16,C18,C18:1,C16OH,C18:1OH,C8,C10:1,C5,C5DC,C4,C14,C14:1,C50H,C3,C5:1

Ausencia de metabolitos anormales Normal

RESULTADOS NORMALES


Recuerde que estas son pruebas de tamizaje que solo indican la probabilidad de que el recién nacido tenga una de las enfermedades estudiadas por el programa y pueden requerir pruebas adicionales para la confirmación de algún diagnóstico. La sensibilidad de estas pruebas se reduce a medida que aumenta la edad del paciente, por esto es conveniente realizarlas dentro del primer mes de nacido.

REVISADO : EDUVILIA JOHANA GOMEZ **PROCESADO :** MARIA JOSE PINZON GARCIA **FECHA :**
Bacterióloga Bacterióloga
Reg. 40.936.003 Reg. 1.015.469.392 18/02/2026

LABORATORIO PREGEN
Carrera 15a No 106-42
BOGOTA

Batch 2065, Rack A, Plate 1, Well E12, 172151
[D83324EACD06ACC0] Feb 04, 2026 13:41:31 Pressure = 85 bar (85 to 87)

FA



| PEAK | RT | REL RT | % CONC | AREA | COMMENT |
|-------------|-------|--------|--------|--------|-------------------|
| 1 | 0.408 | F 0.49 | 1.6% | 11178 | |
| 2 | 0.492 | F 0.59 | 0.7% | 5369 | |
| 3 | 0.838 | F 1.00 | 53.3% | 382620 | Consistent with F |
| 4 | 0.987 | F 1.17 | 2.9% | 20891 | |
| 5 | 1.193 | A 1.00 | 41.5% | 297866 | A peak - REVIEW |
| Total Area: | | | | 717924 | |

- Codes:
- 1) Wide A peak
 - 2) Area of A peak < 80%
 - 3) Peak area greater than expected
 - 4) Peak after A2
 - 5) Alc > 10%
 - 6) HbF or variant present
 - 7) Total sample area too small/big
 - 8) A2 is not within normal range

Dr. MARIA JOSE PINZON GARCIA
RED COLOMBIANA DE MEDICINA GENETICA SAS - PREGEN
BOGOTA
CARRERA 15 A # 106 - 42
11001 BOGOTA
Colombia

Date of Report 17.02.2026
Sample Received 11.02.2026
Date of Sampling 31.01.2026
LAB-ID 262006017

Medical Report

| | | | |
|---------------|-----------------------------------|-----------|----------|
| Patient name | HUERTAS ALVARADO IAN MATEO | Sample-ID | A0362093 |
| Date of Birth | 01.12.2025 | Gender | M |

Indication: Newborn Screening

Method(s): Immunoassay, Tandem mass spectrometry from Dried Blood Spot

Results:

| Parameter | Value | Unit | Reference |
|--|----------|--------|-----------|
| Birth weight (g) | 3720 | g | - |
| 17-hydroxyprogesterone (17OHP) | <5.0 | nmol/L | < 90.0 |
| Thyroid-stimulating hormone (TSH) | 0.7 | μU/mL | < 15.0 |
| Biotinidase | 429.6 | U | > 51.0 |
| Galactose-1-P-uridyltransferase (GALT) | 8.0 | U/g Hb | > 2.5 |
| Immunoreactive trypsinogen (IRT) | <15 | ng/mL | < 65.0 |
| Phenylalanine | 35.2 | μmol/L | < 150.0 |
| Amino acid profile | negative | | - |
| Acylcarnitine profile | negative | | - |

Interpretation: NEGATIVE RESULT

| | |
|---------------|-----------------------------------|
| Patient name | HUERTAS ALVARADO IAN MATEO |
| Date of Birth | 01.12.2025 |

| | |
|-----------|----------|
| Sample-ID | A0362093 |
| Gender | M |

Results:

| Parameter | Value | Unit | Reference |
|--|-------|--------|---------------|
| Phenylalanine (Phe) | 35.2 | µmol/L | < 150.0 |
| Phenylalanine / Tyrosine ratio (Phe/Tyr) | 0.51 | µmol/L | < 2.20 |
| Tyrosine (Tyr) | 68.4 | µmol/L | < 200.0 |
| Leucine (Leu) | 108.6 | µmol/L | < 270.0 |
| Valine (Val) | 55.3 | µmol/L | < 200.0 |
| Methionine (MET) | 25.1 | µmol/L | < 78.0 |
| Methionine / Phenylalanine (Met/Phe) | 0.71 | µmol/L | < 1.60 |
| Citrulline (Cit) | 14.7 | µmol/L | < 50.0 |
| Ornithine (Orn) | 148.8 | µmol/L | < 250.0 |
| Ornithine / Citrulline ratio (Orn/Cit) | 10.12 | µmol/L | 1.50 - 20.00 |
| Proline (Pro) | 97.3 | µmol/L | < 350.0 |
| Alanine (Ala) | 174.1 | µmol/L | < 750.0 |
| Arginine (Arg) | 35.2 | µmol/L | < 100.0 |
| Aspartic acid (Asp) | 91.8 | µmol/L | < 100.0 |
| Glutamic acid (Glu) | 240.5 | µmol/L | < 600.0 |
| Glycamine (Gly) | 171.2 | µmol/L | < 700.0 |
| Free carnitine (C0) | 20.49 | µmol/L | 6.00 - 100.00 |
| acetylcarnitine (C2) | 15.54 | µmol/L | 1.34 - 48.81 |
| propionylcarnitine (C3) | 1.90 | µmol/L | 0.13 - 6.60 |
| butyryl-/isobutyrylcarnitine (C4) | 0.15 | µmol/L | 0.03 - 0.90 |
| isovaleryl-/2-methylbutyrylcarnitine(C5) | 0.09 | µmol/L | 0.02 - 2.00 |
| tiglylcarnitine (C5:1) | 0.01 | µmol/L | < 0.20 |
| hydroxyvalerylcarnitine (C5OH) | 0.20 | µmol/L | 0.02 - 0.57 |
| glutaryl carnitine (C5DC) | 0.02 | µmol/L | < 0.30 |
| hexanoylcarnitine (C6) | 0.06 | µmol/L | 0.01 - 0.13 |
| octanoylcarnitine (C8) | 0.03 | µmol/L | 0.01 - 0.30 |
| decanoylcarnitine (C10) | 0.03 | µmol/L | 0.01 - 0.36 |
| decenoylcarnitine (C10:1) | 0.09 | µmol/L | < 0.30 |
| decadienoylcarnitine (C10:2) | 0.02 | µmol/L | < 0.10 |
| dodecanoylcarnitine (C12) | 0.04 | µmol/L | 0.10 - 0.60 |
| myristoylcarnitine (C14) | 0.07 | µmol/L | 0.01 - 0.57 |
| tetradecenoylcarnitine (C14:1) | 0.06 | µmol/L | 0.10 - 0.38 |
| palmitoylcarnitine (C16) | 0.65 | µmol/L | 0.62 - 7.81 |
| 3-hydroxypalmitoylcarnitine (C16OH) | 0.02 | µmol/L | < 0.10 |
| stearoylcarnitine (C18) | 0.28 | µmol/L | 0.30 - 2.40 |
| oleylcarnitine (C18:1) | 1.88 | µmol/L | 0.06 - 3.86 |
| 3-hydroxystearoylcarnitine (C18OH) | 0.01 | µmol/L | < 0.09 |
| malonylcarnitine (C3DC) | 0.03 | µmol/L | < 0.50 |

Please note: Inconspicuous negative biochemical results cannot exclude any inborn error of metabolism or endocrine disorder with certainty in newborns. We recommend any follow-up or genetic testing if any clinical symptoms are present.

Authorized By: Assoc.-Prof. Dr. Andrea-Romana KASPER, MD, PhD
[Specialist for Pediatrics, Neonatology and Nutrition]

Report was electronically signed and approved.

Contact Details
Assoc.-Prof. Dr. Andrea-Romana KASPER, MD, PhD
E-Mail: info@archimedlife.com

ARCHIMEDlife GmbH
International Medical Laboratory+
Leberstrasse 20/2 | 1110 Vienna, Austria
www.archimedlife.com